INTRODUCTION
Transfusion medicine is an essential part of the history and development of organ transplantation. In the beginning of the solid organ transplantation era, the transfusion of allogeneic blood to transplanted patients was avoided, because leukocytes in the blood product were supposed to induce alloantibodies that are associated with rejection of the allograft (1) . This was the case until 1973, when Opelz et al. (2) identified a significantly better kidney graft survival in recipients of multiple pretransplant allogeneic blood transfusions compared with non-transfused recipients. Surprisingly, it was suggested that this improved outcome was mediated by leukocytes of blood donor origin (3) . Thus, leukocytes seem not only to activate the recipient's immune system leading to alloantibody formation, but can as well suppress the recipient's immune response upon transplantation. The immunological mechanism leading to improved graft outcome is thought to depend on multiple factors, of which one may be the induction of regulatory T cells in case an HLA-DR shared pretransplant blood transfusion is given (4) . In the eighties, the improvement of rejection diagnosis, immunosuppressive therapy and overall patient care questioned the residual benefits of pretransplant blood transfusions (5) . Nevertheless, some studies still showed a beneficial effect of pretransplant blood transfusions in transplanted patients who received potent immunosuppressive drugs (6) (7) (8) (9) (10) , although results were not unequivocal (11) . The detrimental effects of blood transfusion, such as the risk of transmitting infectious diseases and the risk of alloimmunization, also contributed to a reserved pretransplant transfusion policy in many transplant centers. At the Leiden University Medical Center, transfusion pre-treatment was continued for pancreas-kidney transplantation. Patients on the waiting list for simultaneous pancreas-kidney transplantation (SPKT) received an one HLA-DR matched, leukocytecontaining protocolled blood transfusion (PBT) in case there was no prior exposure to alloantigens, e.g. by pregnancies or therapeutic blood transfusions. In this study, we describe the effect of such a deliberate blood transfusion in the cohort of patients who underwent SPKT between 1996 and 2005. During this time period modern immunosuppressive maintenance and induction therapy were introduced to reduce the incidence of acute rejection episodes (12, 13) . Since induction therapy may alter or even abolish transfusion-induced immunomodulation, we also investigated whether it interferes with the effect of PBT.
MATERIALS AND METHODS

Study population
SPKT was performed in a single center between October 1996 and June 2005. All patients who underwent SPKT during this period for insulin dependent type 1 diabetes mellitus and end-stage renal failure were included in this study (n=118). Patients with previous solid organ transplants were excluded. Before transplantation (median 220 days, range 31-1721 days), forty-nine patients received one unit of non-leukocyte depleted packed red blood cells, stored less than 24 hours. Blood donors were selected on basis of one HLA-DR match with the patient and a negative red cell and leukocyte cross match. Sixty-nine patients received no PBT because of previous therapeutical (leukocyte-depleted) transfusions or pregnancy. Post-transplant maintenance immunosuppressive therapy consisted of standard regimens of calcineurin inhibitors, purine synthesis inhibitors and corticosteroids. Induction therapy with polyclonal antithymocyte globulin (ATG)-Fresenius (ATGF; Fresenius AG, Bad Homburg, Germany) or humanized antibodies against the interleukin-2 receptor ΅-chain (daclizumab) was given from 1999 to 2005. To analyze the impact of changing the immunosuppressive regimen over the years, we divided the years of transplantation in year cohorts (1996-1997, 1998-1999, 2000-2001, 2002-2003, and 2004-2005) . Acute rejection episodes of the kidney (within 6 months post-transplant) were biopsyproven. First-line treatment of rejection was 1 g methylprednisolone for three consecutive days. Severe acute rejections (steroid resistant or second episodes) were treated with ATG-Merieux (ATGM; Thymoglobulin®; Genzyme Europe BV, Naarden, The Netherlands) for 10 days guided by CD3 counts in peripheral blood.
Statistics
Statistical analyses were performed using SPSS version 14.0. For comparison between groups, cross tables with two-tailed Fisher's exact tests were used for nominal variables and nonparametric Mann Whitney-U test for scale variables. In order to identify independent prognostic factors for occurrence of acute rejection episodes and its treatment with ATGM, Cox proportional hazard regression with time to acute rejection and ATGM treatment as dependent variables was used. Hazard ratio's (HR) with 95% confidence intervals (CI) are given. P-values less than 0.05 are considered significant.
RESULTS
Characteristics of study population and outcome
This study consisted of 118 patients after SPKT, of whom 49 received a PBT. Characteristics and clinical outcome of the study population are summarized in Table  1 . As expected, there was an imbalance in gender as females were underrepresented in the group of patients who received a PBT (p=0.024). Moreover, time on dialysis differed among both groups as patients who did not receive a PBT had a longer history of dialysis (p=0.041). All other relevant patient characteristics were comparable between the groups. 
Induction therapy decreases the occurrence of acute rejection episodes
In order to identify prognostic factors for occurrence of acute rejection episodes, univariate and multivariate analyses were applied ( Table 2 ). In univariate analysis, induction therapy significantly reduced the number of patients with acute rejection episodes (hazard ratio (HR): 0.371, 95% CI: 0.226-0.610, p<0.001). This is graphically represented in Figure 1A . 
Beneficial effect of protocolled blood transfusion is retained after induction therapy
Since patients were conditioned with induction therapy from 1999 onwards, the effect of a PBT could be evaluated in the groups with and without induction therapy. Patients not treated with induction therapy, had a severe acute rejection episode in 81% (17 out of 21) of the cases when no PBT was given, while a severe acute rejection occurred in 3 out of 8 patients (37.5%) after receiving a PBT (HR: 0.334, 95% CI: 0.097-1.151, p=0.082) ( Figure 1B) . Patients who did receive induction therapy and no PBT needed ATGM rejection treatment in 13 out of 17 cases (76.5%), in comparison with 38.9% (7 out of 18) of patients who did receive a PBT (HR: 0.366, 95% CI: 0.145-0.923, p=0.033) ( Figure 1C ). In the latter group, two patients died within 6 months post-transplant and were excluded for evaluation of severe acute rejection occurrence. Five year graft and patient survival were not different in multivariate analysis between patients without and with a PBT irrespective of induction therapy (data not shown).
DISCUSSION
This retrospective study shows a beneficial effect of PBTs in combined pancreas-kidney transplantation. We evaluated the effect of a one HLA-DR matched PBT on clinical outcome after SPKT. Multivariate analysis depicted a PBT as the major prognostic factor for a lower occurrence of severe acute kidney graft rejections that had to be treated with ATGM. This effect of PBTs was present irrespective of the use of induction treatment. Induction treatment itself significantly reduced the incidence of acute rejection episodes, but not the proportion of severe, refractory rejections. After SPKT, acute rejection of the kidney graft occurs in a substantial number of patients. In our patient population an average of 54% experienced an acute rejection episode of the kidney within the first 6 months after transplantation. Acute rejections of the pancreas graft also occur, but are usually less severe and preceded by kidney graft rejection. From 1999 onwards induction therapy was introduced in our transplantation program in order to reduce acute rejections. Its effectiveness has been shown in several studies (12) (13) (14) (15) and is confirmed in our patients using ATGF or daclizumab induction therapy. Besides the use of ATGF as induction treatment to reduce acute rejections, ATG is often used to treat severe rejection episodes that are in most cases steroid resistant (16) (17) (18) . Different ATG products, derived from two different sources: a rabbit anti-Jurkat cell line (ATGF) and a rabbit anti-human thymocyte line (ATGM), are used for induction therapy and for second line treatment of acute rejections respectively to circumvent serum sickness. The potent immunosuppressive effects of ATG products are associated with prolonged immunodeficiency and increased risk of infections and death (19) (20) (21) (22) (23) . If a PBT would be able to reduce the use of ATGM for severe acute rejections, this may reduce the potential risks for these complications.
Univariate and multivariate analysis revealed that a PBT did not affect the occurrence of acute rejection episodes. This is in agreement with two other studies. A randomised study performed by the group of Hiesse et al. found no beneficial effect of a HLA-DR matched PBT on acute rejection episodes in kidney transplant patients (11) . In an observational study, Stratta et al. found no significant effect of a random pretransplant transfusion on occurrence of acute rejection episodes after SPKT (24) . However, when we looked into more severe acute rejections that required ATGM treatment, we found a beneficial role of a PBT. This effect was present independently of the year of transplantation, despite the increasing use of more potent immunosuppressive drugs that reduce the incidence of rejection. Daclizumab and ATGF act by a different mechanism, however their common goal is to reduce the number of activated recipient T cells able to attack the donor organ. Although the immune mechanism exerting the presumed beneficial role of PBTs in clinical transplantation is still not known, the advantage of HLA-DR compatibility between blood donor and recipient was proposed in several studies (4, 6) . It is hypothesized that CD4 + recipient T cells recognizing an allogeneic peptide in the context of the shared HLA-DR antigen after PBT, can act as regulatory T cells (Tregs) and down-regulate an immune response to the graft (25) (26) (27) . It has been proposed that such recipient Tregs may be inactivated by therapy with either ATGF or daclizumab. Our observation that a clinically relevant beneficial effect of PBTs also exists in patients who received induction therapy (p=0.033) suggests that the beneficial PBT effect is not abolished after induction therapy. Moreover, recent studies emphasize that induction therapy may save the Treg pool and may even be involved in induction of Tregs (28) (29) (30) . A major flaw in our study is the difference in immunologic risk profile between patients with and without a PBT, because the inclusion criteria for PBT select predominantly untransfused males. With respect to alloimmunization as detected by antibody formation, both groups were comparable and showed a low PRA (median: 4%). However, PBT excluded patients may have, by pregnancy and therapeutic transfusions induced, memory cells without detectable alloantibodies, which may play a role causing more aggressive rejections. On the other hand, residual leukocytes in a therapeutic blood transfusion and trafficking of fetal cells into the maternal circulation during pregnancy may have a similar beneficial affect as a PBT. The retrospective nature of our study allowed us to correct only for known risk factors in multivariate analyses, whereas unknown confounders for rejection may still be present. The indication for a PBT did not change during the study interval. Before application of induction treatment in 1999, 32% of the 38 patients received a PBT as compared to 46% of the 80 patients treated after 1999. This difference is not significant but may reflect a tendency for more restrictive therapeutic transfusion triggers over time, resulting in an increase of eligible patients for a PBT after 1999. The causal benefit of a PBT can only be demonstrated in a prospective randomised study. Only three prospective, randomized controlled trials have been performed investigating the blood transfusion effect in solid organ transplantation on graft rejection with unequivocal conclusions (10, 31) , of which one study showing no effect has taken into account the presence of HLA-DR sharing leukocytes in the blood product (11).
In conclusion, a PBT was associated with a reduction in severe acute rejection episodes in patients after SPKT, irrespective of the use of potent immunosuppressive drugs. While induction therapy decreased the occurrence of acute rejections, PBTs seemed to suppress the immune response after transplantation thereby preventing the additional need for ATGM. Only a prospective, randomized controlled study can strengthen our data and investigate a causal role of a PBT in present times of modern immunosuppressive agents.
